Inhibition of HIV-1 Replication by the Ribonuclease, Recombinant Angiogenin
Description of Invention:
This invention describes the inhibition of human immunodeficiency virus-1 (HIV-1) replication by recombinant angiogenin, a ribonuclease (RNase). Ribonucleases have been shown to inhibit HIV-1 replication in chronically-infected cell lines. This invention has demonstrated that angiogenin is a potent inhibitor of HIV-1 replication. For example, angiogenin inhibits HIV-1 replication in primary activated T lymphocyte cultures as well as chronically infected cell lines. Since inhibition of HIV-1 replication in primary activated T lymphocytes would decrease the risk of HIV spreading to other T cells, angiogenin has several advantages over other known ribonucleases that are used to inhibit HIV replication. Furthermore, this invention raised the possibility that angiogenin could be used in lower doses for inhibiting HIV replication and would be less toxic as compared to other ribonucleases. Thus, angiogenin may be an RNase of choice for treating patients with AIDS and this invention would overcome some of the problems involved in current ribonucleolytic HIV treatments.
Inventors:
Drs. Gene Shearer (NCI) Joost J. Oppenheim (NCI) Maria T. Rugeles (NCI) and Susanna M. Rybak (NCI)
For Additional Information Please Contact: Sally Hu PhD MBA
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-5606
Email: hus@mail.nih.gov
Fax: (301) 402-0220
